The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases

Inflammation and Allergy - Drug Targets

Volumn 13, Issue 2, 2014, Pages 121-127

  Toussirot, Éric ^a,b,c   Bereau, Matthieu ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c Hôpital Saint Jacques   (France)

Author keywords

JC virus; Monoclonal antibodies; Natalizumab; Progressive multifocal leukoencephalopathy; Rituximab

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL PRODUCT; EFALIZUMAB; MATHERA; NATALIZUMAB; PROTEIN VP1; RITUXIMAB; UNCLASSIFIED DRUG; ABATACEPT; ADALIMUMAB; BELIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PROTEIN VP2; PROTEIN VP3; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; USTEKINUMAB; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; ANTIINFLAMMATORY AGENT;

CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INFLAMMATORY DISEASE; JC VIRUS; MULTIPLE SCLEROSIS; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; REVIEW; SEROLOGY; VIREMIA; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LEUKOENCEPHALOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; CHEMICALLY INDUCED; CHRONIC DISEASE; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLAMMATION; POLYOMAVIRUS INFECTION; RISK ASSESSMENT; VIROLOGY; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CHRONIC DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATION; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; POLYOMAVIRUS INFECTIONS; RISK ASSESSMENT; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 84903722581     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528113666140224103712     Document Type: Review

References (35)

1. Tan, C.S.; Koralnik, I. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol., 2010, 9(4), 425-437.
2. Berger, J. R.; Houff, S.A.; Major, E. O. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs, 2009, 1(6), 583-589.
3. Boren, E.J.; Cheema, G.S.; Naguwa, S.M.; Ansari, A.A.; Gershwin, M.E. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J. Autoimmun., 2008, 30(1-2), 90-98.
4. Knowles, W.A.; Pipkin, P.; Andrews, N.; Vyse, A.; Minor, P.; Brown, D.W.; Miller, E. Population based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J. Med. Virol., 2003, 71(1), 115-123.
5. Yogo, Y.; Kitamura, T.; Sugimoto, C.; Ueki, T.; Aso, Y.; Hara, K.; Taguchi, F. Isolation of a possible archetypal JC virus DNA sequence from non immunocompromised individuals. J. Virol., 1990, 64(6), 3139-3143.
6. Weber, F.; Goldman, C.; Kramer, M.; Kaup, F.J.; Pickhardt, M.; Young, P.; Petry, H.; Weber, T.; Lüke, W. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann. Neurol., 2001, 49(5), 636-642.
7. Giudici, B.; Vaz, B.; Bossolasco, S.; Casari, S.; Brambilla, A.M.; Lüke, W.; Lazzarin, A.; Weber, T.; Cinque, P. Highly active antiretroviral therapy and progressive multifocal leukoencephalopthy effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin. Infect. Dis., 2000, 30(1), 95-99.
8. Carson, K.R.; Evens, A.M.; Richey, E.A.; Habermann, T.M.; Focosi, D.; Seymour, J.F.; Laubach, J.; Bawn, S.D.; Gordon, L.I.; Winter, J.N.; Furman, R.R.; Vose, J.M.; Zelenetz, A.D.; Mamtani, R.; Raisch, D.W.; Dorshimer, G.W.; Rosen, S.T.; Muro, K.; Gottardi-Littell, N.R.; Talley, R.L.; sartor, O.; Green, D. Major, E.O., Bennett, C.L. Progressive multifocal leukoencephalopthy after rituximab therapy in HIV negative patients. Report of 57 cases from the research on adverse drug events and reports project. Blood, 2009, 113(20), 4834-4840.
9. Lipman, M.; Breen, R. Immune reconstitution inflammatory syndrome in HIV. Curr. Opin. Infect. Dis., 2006, 19(1), 20-25.
10. Calabrese, L.H.; Molloy, E.S. Progressive multifocal leukoencephalopthy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis., 2008, 67(Suppl 3), iii 64-65.
11. Marzocchetti, A.; Wutrich, C.; Tan, C.S.; Tompkins, T.; Bernal- Cano, F.; Bhargava, P.; Ropper, A.H.; Koralnik, I.J. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J. Neurovirol., 2008, 14(5), 455-458.
12. Warnke, C.; Menge, T.; Hartung, H.P.; Racke, M.K.; Cravens, P.D.; Bennett, J.L.; Frohman, E.M.; Greenberg, B.M.; Zamvil, S.S.; Gold, R.; Hemmer, B.; Kieseier, B.C.; Stüve, O. Natalizumab and progressive multifocal leukoencephalopathy. What are the causal factors and can it be avoided? Arch. Neurol., 2010, 67(8), 923-930.
13. Koralnik, I.J.; Du Pasquier, R.A.; Letvin, N.L. JC virus specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopthy. J. Virol., 2001, 75 (7), 3483-3487.
14. Eng, P.M.; Turnbull, B.R.; Cook, S.F.; Davidson, J.E.; Kurth, T.; Seeger, J.D. Characteristics and antecedents of progressive multifocal leukoencephalopthy in an insured population. Neurology, 2006, 67(5), 884-886.
15. Molloy, E.S.; Calabrese, L.H. Progressive multifocal leukoencephalopthy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum., 2009, 60(12), 3761-3765.
16. Calabrese, L.H.; Molloy, E.S.; Huang, De.R.; Ransohoff R.M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum., 2007, 56(7), 2116-2128.
17. Palazzo, E.; Yahia, S.A. Progressive multifocal leukoencephalopthy in autoimmune diseases. Joint Bone Spine, 2012, 79(4), 351-355.
18. Von Andrian, U.H.; Engelhard, B. Alpha 4 integrins as therapeutic targets in autoimmune disease. N. Engl. J. Med., 2003, 348(1), 68-72.
19. Yousry, T.A.; Major, E.O.; Ryschlewitsch, C.; Fahle, G.; Fisher, S.; Hou, J.; Curfman, B.; Miszkiel, K.; Mueller-Lenke, N.; sanchez, E.; Barkhof, F.; RAdue, E.W.; Jäger, H.R., Clifford, D.B. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med., 2006, 354(9), 924-933.
20. Bloomgren, G.; Richman, S.; Hotrmans, C.; Subramanyan, M.; Goelz, S.; Natarajan, A.; Lee, S.; Plavina, T.; Scanlon, J.V.; Sandrock, A.; Bozic, C. Risk of natalizumab -associated progressive multifocal leukoencephalopathy. N. Eng. J. Med., 2012, 366(20), 1870-1880.
21. Krumbholz, M.; Meinl, I.; Kumpfel, T.; Hohlfeld, R.; Meinl, E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology, 2008, 71(17), 1350-1354.
22. Lichterfeld, M.; Martin, S.; Burkly, L.; Haas, R.; Kronenwett, R. Mobilization of CD34+haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br. J. Haematol., 2000, 110(1), 71-81.
23. Stuve, O.; Marra, C.M.; Bar-Or, A.; Niino, M.; Cravens, P.D.; Cepok, S.; Frohman, E.M.; Phillips, J.T.; Arendt, G.; Jerome, K.R.; Cook, L.; Grand'Maison, F, Hemmer, B.; Monson, N.L.; Racke, M.K. Altered CD4/CD8 + T cells ratios in cerebrospinal fluid of natalalizumab treated patients with multiple sclerosis. Arch Neurol., 2006, 63(10), 1383-1387.
24. Molloy, E.S.; Calabrese, L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases. Evolving role of biologic therapies. Arthritis Rheum., 2012, 64(9), 3043-3051.
25. Clifford, D.B.; Ances, B.; Costello, C.; Rosen-Schmidt, S.; Andersson, M.; Parks, D.; Perry, A.; Yerra, R.; Schmidt, R.; Alvarez, E.; Tyler, K.L. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol., 2011, 68(9), 1156-1164.
26. Kothary, N.; Diak, I.L.; Brinker, A.; Bezabeth, S.; Avigan, M.; Dal Pan, G. Progressive multifocal leukoencephalopthy associated with efalizumab use in psoriasis patients. J. Am. Acad Dermatol., 2011, 65(3), 546-541.
27. Martin, S.L.; Matty, F.M.; FiumaraK.; Trcon, S.P.; Gribben, J.G.; Baden, I.R. Infectious complications associated with alemtuzumab use for lymphoprolifertaive disorders. Clin. Infect. Dis., 2006, 43(1), 16-24.
28. Gallamini, A.; Zaja, F.; Patti, C.; Billio, A.; Specchia, M.R.; Tucci, A.; Levis, A.; Manna, A.; Secondo, V.; Rigacci, L.; Pinto, A.; Iannitto, E.; Zoli, V.; Torchio, P.; Pileri, S.; Tarella; C. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first line treatment of peripheral T-cell lypmphoma: results of a GITIL (Gruppo Italiano Terapies Innovative nci Linformi) prospective multicentre trial. Blood, 2007, 110(7), 2316-2323.
29. Waggoner, J.; Mattinu, T.; Palmer S.M. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplantation. J. Heart Lung Transplant., 2009, 28(4), 395-398.
30. Isidoro, L.; Pires, P.; Rito, L.; Cordeiro, G. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia treated with alemtuzumab. BMJ Case Rep., 2014, Jan 8; doi:10.1136/bcr-2013-201781.
31. Bharat, A.; Xie, F.; Baddley, J.W.; Beukelman, T.; Chen, L.; Calabrese, L.; Delzell, E.; Grijalva, C.G.; Patkar, N.M.; Saag, K.; Winthrop, K.L.; Curtis, J.R. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res., 2012, 64(4), 612-615.
32. Lee, P.; Plavina, T.; Castro, A.; Berman, M.; Jaiswal, D.; Rivas, S.; Schlain, B.; Subramanyam, D. A second generation ELISA (STRATIFY JCV™ Dxselect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J. Clin. Virol., 2013, 57(2), 141-146.
33. Trampe, A.K.; Hemmelmann, C.; Stroet, A.; Haghikia, A.; Hellwig, K.; Wiendl, H.; Goelz, S.; Ziegler, A.; Gold, R.; Chan, A. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology, 2012, 78(22), 1736-1742.
34. Plavina, T.; Subramanyam, M.; Bloomgren, G.; Richman, S.; Pace, A.; Lee, S.; Schlain, B.; Campagnolo, D.; Belachew, S.; Ticho, B. Anti-JCV antibody index further defines PML risk in natalizumabtreated MS patients. 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers. 29 May - 1 June 2013, Orlando, FL, USA. Available at: https://cmscactrims.confex.com/cmscactrims/2013/webprogram/Paper1642.html (Access date 11 February 2014).
35. Warnke, C.; Ramanujam, R.; Plavina, T.; Bergström, T.; Goelz, S.; Subramanyam, M.; Kockum, I.; Rahbar, A; Kieseier, B.C.; Holmén, C.; Olsson, T.; Hillert, J.; Fogdell-Hahn A. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J. Neurol. Neurosurg. Psychiatry, 2013; 84(11), 1199-1205.